Viatris (VTRS) reported Q3 adjusted earnings Thursday of $0.75 per diluted share, compared with $0.79 a year earlier.
Analysts surveyed by Capital IQ expected $0.68.
Revenue for the quarter ended Sept. 30 was $3.74 billion, compared with $3.93 billion a year earlier. Analysts surveyed by Capital IQ expected $3.71 billion.
For full-year 2024, the pharmaceutical company said it expects adjusted EPS of $2.56 to $2.71, down from previous guidance of $2.58 to $2.73. It also maintained its revenue guidance of $14.6 billion to $15.1 billion.
Analysts surveyed by Capital IQ expect full-year adjusted EPS of $2.68 on revenue of $14.83 billion.
Shares of Viatris were gaining over 1% in recent premarket activity.
Price: 11.79, Change: +0.18, Percent Change: +1.55
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.